{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T07:51:05Z","timestamp":1794124265758,"version":"4.8.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41574-026-01258-5","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:06:57Z","timestamp":1779354417000},"page":"530-542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Causes and consequences of discontinuation of GLP1RAs or tirzepatide"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-3203","authenticated-orcid":false,"given":"Antonio","family":"Ceriello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2959-2658","authenticated-orcid":false,"given":"Francesco","family":"Prattichizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1489-2018","authenticated-orcid":false,"given":"Abdul Raouf","family":"Mastan Sheik Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"La Grotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare Celeste","family":"Berra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0583-3717","authenticated-orcid":false,"given":"Alicia","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4441-9511","authenticated-orcid":false,"given":"Neale","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5749-6954","authenticated-orcid":false,"given":"Michael Albrecht","family":"Nauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina Tiziana","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"1258_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera, F. B. et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am. J. Prevent. Cardiol. 18, 100679 (2024).","journal-title":"Am. J. Prevent. Cardiol."},{"key":"1258_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng, Z. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct. Target. Ther. 9, 234 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1258_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker, D. J. GLP-1 physiology informs the pharmacotherapy of obesity. Mol. Metab. 57, 101351 (2022).","journal-title":"Mol. Metab."},{"key":"1258_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653\u2013662 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1258_CR5","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","volume":"35","author":"JE Campbell","year":"2023","unstructured":"Campbell, J. E. et al. GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab. 35, 1519\u20131529 (2023).","journal-title":"Cell Metab."},{"key":"1258_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4093\/dmj.2025.0106","volume":"49","author":"JS Park","year":"2025","unstructured":"Park, J. S., Kim, K. S. & Choi, H. J. Glucagon-like peptide-1 and hypothalamic regulation of satiation: cognitive and neural insights from human and animal studies. Diabetes Metab. J. 49, 333\u2013347 (2025).","journal-title":"Diabetes Metab. J."},{"key":"1258_CR7","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/ijms24021703","volume":"24","author":"R Nevola","year":"2023","unstructured":"Nevola, R. et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int. J. Mol. Sci. 24, 1703 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1258_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","volume":"48","author":"HJ Wong","year":"2025","unstructured":"Wong, H. J. et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care 48, 292\u2013300 (2025).","journal-title":"Diabetes Care"},{"key":"1258_CR9","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/oby.24002","volume":"32","author":"XH Pan","year":"2024","unstructured":"Pan, X. H. et al. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obesity 32, 840\u2013856 (2024).","journal-title":"Obesity"},{"key":"1258_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2025.109045","volume":"39","author":"M Ibrahim","year":"2025","unstructured":"Ibrahim, M. et al. Obesity and its management in primary care setting. J. Diabetes Complications 39, 109045 (2025).","journal-title":"J. Diabetes Complications"},{"key":"1258_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial. N. Engl. J. Med. 389, 514\u2013526 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1258_CR12","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1258_CR13","unstructured":"National Institute for Health and Care Excellence. Semaglutide for managing overweight and obesity. NICE https:\/\/www.nice.org.uk\/consultations\/1621\/1\/recommendations (2022)."},{"key":"1258_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427\u2013437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1258_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve, S. V. et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 13, 15\u201328 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1258_CR16","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink, H. J. L. et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10, 774\u2013785 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1258_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jcag\/gwae057","volume":"8","author":"KJ Potter","year":"2025","unstructured":"Potter, K. J., Phinney, J., Kulai, T. & Munro, V. Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Can. Assoc. Gastroenterol. 8, 47\u201357 (2025).","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"1258_CR18","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"Hartman, M. L. et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43, 1352\u20131355 (2020).","journal-title":"Diabetes Care"},{"key":"1258_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/dom.12085","volume":"15","author":"B Wang","year":"2013","unstructured":"Wang, B. et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes. Metab. 15, 737\u2013749 (2013).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao, H. et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 384, e076410076410 (2024).","journal-title":"BMJ"},{"key":"1258_CR21","doi-asserted-by":"publisher","first-page":"zsae280","DOI":"10.1093\/sleep\/zsae280","volume":"48","author":"M Li","year":"2025","unstructured":"Li, M. et al. Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis. Sleep 48, zsae280 (2025).","journal-title":"Sleep"},{"key":"1258_CR22","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"American Diabetes Association Professional Practice Committee.","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2025. Diabetes Care 48, S207\u2013S238 (2025).","journal-title":"Diabetes Care"},{"key":"1258_CR23","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.2337\/dc25-S008","volume":"48","author":"American Diabetes Association Professional Practice Committee.","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 8 Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025. Diabetes Care 48, S167\u2013S180 (2025).","journal-title":"Diabetes Care"},{"key":"1258_CR24","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","volume":"66","author":"M Anson","year":"2023","unstructured":"Anson, M. et al. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. Diabetologia 66, 1869\u20131881 (2023).","journal-title":"Diabetologia"},{"key":"1258_CR25","doi-asserted-by":"publisher","first-page":"111979","DOI":"10.1016\/j.diabres.2024.111979","volume":"219","author":"N Cohen","year":"2025","unstructured":"Cohen, N., Yeung, A. & Jenkins, A. Real-world experience of adjunct weekly semaglutide in type 1 diabetes. Is it worth it? Diabetes Res. Clin. Pract. 219, 111979 (2025).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1258_CR26","doi-asserted-by":"publisher","first-page":"q1645","DOI":"10.1136\/bmj.q1645","volume":"386","author":"E Mahase","year":"2024","unstructured":"Mahase, E. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ 386, q1645 (2024).","journal-title":"BMJ"},{"key":"1258_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.diabres.2014.01.010","volume":"103","author":"M Monami","year":"2014","unstructured":"Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I. & Mannucci, E. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res. Clin. Pract. 103, 269\u2013275 (2014).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1258_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2337\/dc20-1815","volume":"44","author":"MA Bethel","year":"2021","unstructured":"Bethel, M. A. et al. HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care 44, 290\u2013296 (2021).","journal-title":"Diabetes Care"},{"key":"1258_CR29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/oby.23952","volume":"32","author":"H Gasoyan","year":"2024","unstructured":"Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P. & Rothberg, M. B. Early- and later-stage persistence with antiobesity medications: a retrospective cohort study. Obesity 32, 486\u2013493 (2024).","journal-title":"Obesity"},{"key":"1258_CR30","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1007\/s00125-025-06439-x","volume":"68","author":"CE Lim","year":"2025","unstructured":"Lim, C. E., Pasternak, B., Eliasson, B. & Ueda, P. Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes. Diabetologia 68, 1680\u20131695 (2025).","journal-title":"Diabetologia"},{"key":"1258_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172","volume":"7","author":"D Do","year":"2024","unstructured":"Do, D. et al. GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes. JAMA Netw. Open 7, e24131723172 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1258_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","volume":"8","author":"PJ Rodriguez","year":"2025","unstructured":"Rodriguez, P. J. et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw. Open 8, e245734957349 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1258_CR33","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","volume":"184","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez, P. J. et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern. Med. 184, 1056\u20131064 (2024).","journal-title":"JAMA Intern. Med."},{"key":"1258_CR34","first-page":"669","volume":"25","author":"E Durden","year":"2019","unstructured":"Durden, E., Liang, M., Fowler, R., Panton, U. H. & Mocevic, E. The effect of early response to GLP-1 RA therapy on long-term adherence and persistence among type 2 diabetes patients in the United States. J. Manag. Care Spec. Pharm. 25, 669\u2013680 (2019).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"1258_CR35","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/PPA.S277676","volume":"14","author":"T Weiss","year":"2020","unstructured":"Weiss, T. et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer. Adherence 14, 2337\u20132345 (2020).","journal-title":"Patient Prefer. Adherence"},{"key":"1258_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s13300-016-0224-5","volume":"8","author":"V Divino","year":"2017","unstructured":"Divino, V. et al. GLP-1 RA treatment patterns among type 2 diabetes patients in five European countries. Diabetes Ther. 8, 115\u2013128 (2017).","journal-title":"Diabetes Ther."},{"key":"1258_CR37","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2666-7568(23)00164-2","volume":"4","author":"ME Malik","year":"2023","unstructured":"Malik, M. E. et al. Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longev. 4, e552\u2013e560 (2023).","journal-title":"Lancet Healthy Longev."},{"key":"1258_CR38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/DMSO.S141235","volume":"10","author":"MV Sikirica","year":"2017","unstructured":"Sikirica, M. V. et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab. Syndr. Obes. 10, 403\u2013412 (2017).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"1258_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2337\/ds20-0025","volume":"34","author":"W Polonsky","year":"2021","unstructured":"Polonsky, W., Gamble, C., Iyer, N., Martin, M. & Hamersky, C. Exploring why people with type 2 diabetes do or do not persist with glucagon-like peptide-1 receptor agonist therapy: a qualitative study. Diabetes Spectr. 34, 175\u2013183 (2021).","journal-title":"Diabetes Spectr."},{"key":"1258_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1149328","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Front. Endocrinol. 14, 1149328 (2023).","journal-title":"Front. Endocrinol."},{"key":"1258_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2337\/diaspect.28.4.283","volume":"28","author":"SC Jones","year":"2015","unstructured":"Jones, S. C., Ryan, D. L., Pratt, V. S., Niak, A. & Brinker, A. D. Injection-site nodules associated with the use of exenatide extended-release reported to the U.S. Food and Drug Administration adverse event reporting system. Diabetes Spectr. 28, 283\u2013288 (2015).","journal-title":"Diabetes Spectr."},{"key":"1258_CR42","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/dom.12885","volume":"19","author":"H Storgaard","year":"2017","unstructured":"Storgaard, H., Cold, F., Gluud, L. L., Vilsboll, T. & Knop, F. K. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes. Metab. 19, 906\u2013908 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He, L. et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern. Med. 182, 513\u2013519 (2022).","journal-title":"JAMA Intern. Med."},{"key":"1258_CR44","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/jcm12010145","volume":"12","author":"JJ Gorgojo-Martinez","year":"2022","unstructured":"Gorgojo-Martinez, J. J. et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J. Clin. Med. 12, 145 (2022).","journal-title":"J. Clin. Med."},{"key":"1258_CR45","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1210\/en.2009-1272","volume":"151","author":"L Bjerre Knudsen","year":"2010","unstructured":"Bjerre Knudsen, L. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151, 1473\u20131486 (2010).","journal-title":"Endocrinology"},{"key":"1258_CR46","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dom.15382","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii, G. A. et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 26, 891\u2013900 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR47","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/dom.70291","volume":"28","author":"T Vilsboll","year":"2026","unstructured":"Vilsboll, T. et al. Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. Diabetes Obes. Metab. 28, 1499\u20131507 (2026).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR48","doi-asserted-by":"publisher","first-page":"e2080","DOI":"10.1210\/clinem\/dgae722","volume":"110","author":"CA Kelly","year":"2025","unstructured":"Kelly, C. A. & Sipos, J. A. Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists. J. Clin. Endocrinol. Metab. 110, e2080\u2013e2087 (2025).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1258_CR49","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/ph18020214","volume":"18","author":"HA Thaibah","year":"2025","unstructured":"Thaibah, H. A., Banji, O. J. F., Banji, D. & Alshammari, T. M. Diabetic ketoacidosis and the use of new hypoglycemic groups: real-world evidence utilizing the Food and Drug Administration adverse event reporting system. Pharmaceuticals 18, 214 (2025).","journal-title":"Pharmaceuticals"},{"key":"1258_CR50","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2169\/internalmedicine.7266-21","volume":"61","author":"S Masuda","year":"2022","unstructured":"Masuda, S. et al. Clinical characteristics associated with the development of diabetic ketoacidosis in patients with type 2 diabetes. Intern. Med. 61, 1125\u20131132 (2022).","journal-title":"Intern. Med."},{"key":"1258_CR51","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/14740338.2024.2419989","volume":"24","author":"ZY Luo","year":"2025","unstructured":"Luo, Z. Y. et al. Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology. Expert Opin. Drug Saf. 24, 287\u2013296 (2025).","journal-title":"Expert Opin. Drug Saf."},{"key":"1258_CR52","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jamaophthalmol.2025.1455","volume":"143","author":"R Shor","year":"2025","unstructured":"Shor, R. et al. Glucagon-Like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration. JAMA Ophthalmol. 143, 587\u2013594 (2025).","journal-title":"JAMA Ophthalmol."},{"key":"1258_CR53","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/aos.17473","volume":"103","author":"A Amini","year":"2025","unstructured":"Amini, A., Hamann, S. & Larsen, M. Semaglutide and non-arteritic anterior ischaemic optic neuropathy: review and interpretation of reported association. Acta Ophthalmologica 103, 615\u2013621 (2025).","journal-title":"Acta Ophthalmologica"},{"key":"1258_CR54","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/ceo.13393","volume":"47","author":"SW Lim","year":"2019","unstructured":"Lim, S. W., van Wijngaarden, P., Harper, C. A. & Al-Qureshi, S. H. Early worsening of diabetic retinopathy due to intensive glycaemic control. Clin. Exp. Ophthalmol. 47, 265\u2013273 (2019).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"1258_CR55","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1258_CR56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1258_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/ceo.14445","volume":"53","author":"I Kapoor","year":"2025","unstructured":"Kapoor, I., Sarvepalli, S. M., D\u2019Alessio, D. A. & Hadziahmetovic, M. Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: a meta-analysis of clinical studies emphasising retinal changes as a primary outcome. Clin. Exp. Ophthalmol. 53, 67\u201375 (2025).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"1258_CR58","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/dom.70200","volume":"28","author":"H Tesfaye","year":"2026","unstructured":"Tesfaye, H. et al. GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: a population-based study. Diabetes Obes. Metab. 28, 1517\u20131528 (2026).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR59","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2337\/dc22-1710","volume":"46","author":"T Heise","year":"2023","unstructured":"Heise, T. et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care 46, 998\u20131004 (2023).","journal-title":"Diabetes Care"},{"key":"1258_CR60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","volume":"26","author":"IJ Neeland","year":"2024","unstructured":"Neeland, I. J., Linge, J. & Birkenfeld, A. L. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes. Metab. 26, 16\u201327 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR61","doi-asserted-by":"publisher","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield, S. B. et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw. Open 4, e2033457 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1258_CR62","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.16364","volume":"27","author":"RW Thomsen","year":"2025","unstructured":"Thomsen, R. W., Mailhac, A., Lohde, J. B. & Pottegard, A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes. Metab. 27, 66\u201388 (2025).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR63","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/pds.3423","volume":"22","author":"M Kulldorff","year":"2013","unstructured":"Kulldorff, M. et al. Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol. Drug Saf. 22, 517\u2013523 (2013).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"1258_CR64","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.14336\/AD.2019.0303","volume":"10","author":"L Gao","year":"2019","unstructured":"Gao, L. et al. Neurological manifestation of incretin-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. Aging Dis. 10, 1311\u20131319 (2019).","journal-title":"Aging Dis."},{"key":"1258_CR65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41591-023-02669-x","volume":"30","author":"SW Waldrop","year":"2024","unstructured":"Waldrop, S. W., Johnson, V. R. & Stanford, F. C. Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity. Nat. Med. 30, 22\u201325 (2024).","journal-title":"Nat. Med."},{"key":"1258_CR66","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","volume":"407","author":"MA Nauck","year":"2026","unstructured":"Nauck, M. A., Tuttle, K. R., Tschop, M. H. & Bluher, M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet 407, 892\u2013908 (2026).","journal-title":"Lancet"},{"key":"1258_CR67","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.2337\/dc24-1082","volume":"47","author":"L Ladebo","year":"2024","unstructured":"Ladebo, L. et al. Real-world use of semaglutide for weight management: patient characteristics and dose titration \u2013 a Danish cohort study. Diabetes Care 47, 1834\u20131837 (2024).","journal-title":"Diabetes Care"},{"key":"1258_CR68","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2337\/dc14-0024","volume":"37","author":"B Ahren","year":"2014","unstructured":"Ahren, B. et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 37, 2141\u20132148 (2014).","journal-title":"Diabetes Care"},{"key":"1258_CR69","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. 385, 896\u2013907 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1258_CR70","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey, W. T. et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat. Med. 28, 2083\u20132091 (2022).","journal-title":"Nat. Med."},{"key":"1258_CR71","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1258_CR72","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1111\/dom.16552","volume":"27","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. Glucagon-like peptide-1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity. Diabetes Obes. Metab. 27, 5042\u20135051 (2025).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR73","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies, M. et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397, 971\u2013984 (2021).","journal-title":"Lancet"},{"key":"1258_CR74","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey, W. T. et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402, 613\u2013626 (2023).","journal-title":"Lancet"},{"key":"1258_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70063","volume":"17","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Sex differences in the efficacy of glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis. J. Diabetes 17, e70063 (2025).","journal-title":"J. Diabetes"},{"key":"1258_CR76","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1507\/endocrj.EJ16-0552","volume":"64","author":"Y Onishi","year":"2017","unstructured":"Onishi, Y., Oura, T., Matsui, A., Matsuura, J. & Iwamoto, N. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan. Endocr. J. 64, 553\u2013560 (2017).","journal-title":"Endocr. J."},{"key":"1258_CR77","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/dom.13086","volume":"20","author":"B Gallwitz","year":"2018","unstructured":"Gallwitz, B. et al. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes. Metab. 20, 409\u2013418 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR78","doi-asserted-by":"publisher","first-page":"e028238","DOI":"10.1136\/bmjopen-2018-028238","volume":"9","author":"SH Mohammed","year":"2019","unstructured":"Mohammed, S. H. et al. Neighbourhood socioeconomic status and overweight\/obesity: a systematic review and meta-analysis of epidemiological studies. BMJ Open 9, e028238 (2019).","journal-title":"BMJ Open"},{"key":"1258_CR79","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/ije\/dyr029","volume":"40","author":"E Agardh","year":"2011","unstructured":"Agardh, E., Allebeck, P., Hallqvist, J., Moradi, T. & Sidorchuk, A. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. Int. J. Epidemiol. 40, 804\u2013818 (2011).","journal-title":"Int. J. Epidemiol."},{"key":"1258_CR80","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2337\/cd22-0100","volume":"41","author":"A Yaseen","year":"2023","unstructured":"Yaseen, A. & Lahiri, S. W. Health care provider prescribing habits and barriers to use of new type 2 diabetes medications: a single-system survey study. Clin. Diabetes 41, 490\u2013501 (2023).","journal-title":"Clin. Diabetes"},{"key":"1258_CR81","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2337\/cd23-0023","volume":"41","author":"HP Whitley","year":"2023","unstructured":"Whitley, H. P., Trujillo, J. M. & Neumiller, J. J. Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages. Clin. Diabetes 41, 467\u2013473 (2023).","journal-title":"Clin. Diabetes"},{"key":"1258_CR82","doi-asserted-by":"publisher","first-page":"e245015","DOI":"10.1001\/jamahealthforum.2024.5015","volume":"6","author":"TJ Mattingly 2nd","year":"2025","unstructured":"Mattingly, T. J. 2nd & Conti, R. M. Marketing and safety concerns for compounded GLP-1 receptor agonists. JAMA Health Forum 6, e245015 (2025).","journal-title":"JAMA Health Forum"},{"key":"1258_CR83","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.3390\/jcm13206256","volume":"13","author":"ARN Ibrahim","year":"2024","unstructured":"Ibrahim, A. R. N. & Orayj, K. M. Impact of ADA guidelines and medication shortage on GLP-1 receptor agonists prescribing trends in the UK: a time-series analysis with country-specific insights. J. Clin. Med. 13, 6256 (2024).","journal-title":"J. Clin. Med."},{"key":"1258_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101962","volume":"58","author":"M Luli","year":"2023","unstructured":"Luli, M. et al. The implications of defining obesity as a disease: a report from the Association for the Study of Obesity 2021 annual conference. EClinicalMedicine 58, 101962 (2023).","journal-title":"EClinicalMedicine"},{"key":"1258_CR85","unstructured":"World Health Organization. Obesity and overweight. WHO https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (2025)."},{"key":"1258_CR86","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding, J. P. H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes. Metab. 24, 1553\u20131564 (2022).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR87","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-024-01547-0","volume":"15","author":"AL McKenzie","year":"2024","unstructured":"McKenzie, A. L. & Athinarayanan, S. J. Impact of glucagon-like peptide 1 agonist deprescription in type 2 diabetes in a real-world setting: a propensity score matched cohort study. Diabetes Ther. 15, 843\u2013853 (2024).","journal-title":"Diabetes Ther."},{"key":"1258_CR88","doi-asserted-by":"publisher","first-page":"111740111740","DOI":"10.1016\/j.diabres.2024.111740","volume":"213","author":"N Nanayakkara","year":"2024","unstructured":"Nanayakkara, N., Lh Huang, M., Jenkins, A. J. & Cohen, N. D. The impact of GLP-1 receptor agonist shortages on glycaemic control: findings from an Australian specialist diabetes clinic. Diabetes Res. Clin. Pract. 213, 111740111740 (2024).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1258_CR89","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1111\/dom.15038","volume":"25","author":"H Jung","year":"2023","unstructured":"Jung, H. et al. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: a retrospective analysis of the diabetes prospective follow-up registry. Diabetes Obes. Metab. 25, 1813\u20131822 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR90","doi-asserted-by":"publisher","first-page":"103680103680","DOI":"10.1016\/j.eclinm.2025.103680","volume":"90","author":"CC Tzang","year":"2025","unstructured":"Tzang, C. C. et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine 90, 103680103680 (2025).","journal-title":"EClinicalMedicine"},{"key":"1258_CR91","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock, J. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398, 143\u20131556 (2021).","journal-title":"Lancet"},{"key":"1258_CR92","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/dom.15325","volume":"26","author":"J Rosenstock","year":"2024","unstructured":"Rosenstock, J. et al. Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS-1 monotherapy trial. Diabetes Obes. Metab. 26, 396\u2013399 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR93","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne, L. J. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 393, 26\u201336 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1258_CR94","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne, L. J. et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 331, 38\u20134824945 (2024).","journal-title":"JAMA"},{"key":"1258_CR95","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/oby.24331","volume":"33","author":"H Gasoyan","year":"2025","unstructured":"Gasoyan, H. et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity 33, 1657\u20131667 (2025).","journal-title":"Obesity"},{"key":"1258_CR96","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.2337\/dc24-0491","volume":"47","author":"SE Kahn","year":"2024","unstructured":"Kahn, S. E. et al. Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the select trial. Diabetes Care 47, 1350\u20131359 (2024).","journal-title":"Diabetes Care"},{"key":"1258_CR97","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff, A. M. et al. Tirzepatide for obesity treatment and diabetes prevention. N. Engl. J. Med. 392, 958\u2013971 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1258_CR98","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.2337\/dc23-0872","volume":"46","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock, J. et al. Achieving normoglycemia with tirzepatide: analysis of SURPASS 1-4 Trials. Diabetes Care 46, 1986\u20131992 (2023).","journal-title":"Diabetes Care"},{"key":"1258_CR99","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s13300-025-01759-y","volume":"16","author":"GP Fadini","year":"2025","unstructured":"Fadini, G. P. The clock is still ticking: tirzepatide and the myth of halting the natural history of type 2 diabetes. Diabetes Ther. 16, 1529\u20131531 (2025).","journal-title":"Diabetes Ther."},{"key":"1258_CR100","doi-asserted-by":"publisher","first-page":"101499","DOI":"10.1016\/j.lanepe.2025.101499","volume":"59","author":"GP Fadini","year":"2025","unstructured":"Fadini, G. P. et al. Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study. Lancet Reg. Health Eur. 59, 101499 (2025).","journal-title":"Lancet Reg. Health Eur."},{"key":"1258_CR101","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00125-023-06048-6","volume":"67","author":"EW Gregg","year":"2024","unstructured":"Gregg, E. W. et al. Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study. Diabetologia 67, 459\u2013469 (2024).","journal-title":"Diabetologia"},{"key":"1258_CR102","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S2213-8587(24)00396-6","volume":"13","author":"J Wagen Hauge","year":"2025","unstructured":"Wagen Hauge, J. et al. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 13, 397\u2013409 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1258_CR103","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2337\/db24-0166","volume":"74","author":"GT Russo","year":"2025","unstructured":"Russo, G. T. et al. When does metabolic memory start? Insights from the association of medical diabetologists annals initiative on stringent HbA1c targets. Diabetes 74, 75\u201381 (2025).","journal-title":"Diabetes"},{"key":"1258_CR104","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/8056440","volume":"2024","author":"I Abdullah Bin Ahmed","year":"2024","unstructured":"Abdullah Bin Ahmed, I. A comprehensive review on weight gain following discontinuation of glucagon-like peptide-1 receptor agonists for obesity. J. Obes. 2024, 8056440 (2024).","journal-title":"J. Obes."},{"key":"1258_CR105","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies, M. J. et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the scale diabetes randomized clinical trial. JAMA 314, 687\u2013699 (2015).","journal-title":"JAMA"},{"key":"1258_CR106","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer, X. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373, 11\u201322 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1258_CR107","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux, C. W. et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389, 1399\u201314097 (2017).","journal-title":"Lancet"},{"key":"1258_CR108","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/liv.14065","volume":"39","author":"J Khoo","year":"2019","unstructured":"Khoo, J. et al. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int. 39, 941\u2013949 (2019).","journal-title":"Liver Int."},{"key":"1258_CR109","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly, A. S. et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N. Engl. J. Med. 382, 2117\u20132128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1258_CR110","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino, D. et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325, 1414\u20131425 (2021).","journal-title":"JAMA"},{"key":"1258_CR111","doi-asserted-by":"publisher","first-page":"e13929","DOI":"10.1111\/obr.13929","volume":"26","author":"S Berg","year":"2025","unstructured":"Berg, S., Stickle, H., Rose, S. J. & Nemec, E. C. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis. Obes. Rev. 26, e13929 (2025).","journal-title":"Obes. Rev."},{"key":"1258_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04200-0","volume":"23","author":"H Wu","year":"2025","unstructured":"Wu, H., Yang, W., Guo, T., Cai, X. & Ji, L. Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications. BMC Med. 23, 398 (2025).","journal-title":"BMC Med."},{"key":"1258_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000545547","volume":"18","author":"T Avcilar","year":"2025","unstructured":"Avcilar, T. 32nd European congress on obesity (ECO 2025). Obes. Facts 18, 1\u2013656 (2025).","journal-title":"Obes. Facts"},{"key":"1258_CR114","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/eurjpc\/zwad072","volume":"30","author":"A Ceriello","year":"2023","unstructured":"Ceriello, A. et al. Risk factor variability and cardiovascular risk among patients with diabetes: a nationwide observational study. Eur. J. Prevent. Cardiol. 30, 719\u2013727 (2023).","journal-title":"Eur. J. Prevent. Cardiol."},{"key":"1258_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101740","volume":"4","author":"SS Dani","year":"2025","unstructured":"Dani, S. S. et al. An observational study of cardiovascular outcomes of tirzepatide vs glucagon-like peptide-1 receptor agonists. JACC Adv. 4, 101740 (2025).","journal-title":"JACC Adv."},{"key":"1258_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112162","volume":"223","author":"TJ Dunn","year":"2025","unstructured":"Dunn, T. J. et al. Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: a retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Diabetes Res. Clin. Pract. 223, 112162 (2025).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1258_CR117","doi-asserted-by":"publisher","first-page":"154799","DOI":"10.1016\/j.metabol.2021.154799","volume":"120","author":"F Prattichizzo","year":"2021","unstructured":"Prattichizzo, F., de Candia, P. & Ceriello, A. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Metabolism 120, 154799 (2021).","journal-title":"Metabolism"},{"key":"1258_CR118","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"J Deanfield","year":"2025","unstructured":"Deanfield, J. et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet 406, 2257\u20132268 (2025).","journal-title":"Lancet"},{"key":"1258_CR119","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","volume":"136","author":"MA Nauck","year":"2017","unstructured":"Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M. & Drucker, D. J. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136, 849\u2013870 (2017).","journal-title":"Circulation"},{"key":"1258_CR120","doi-asserted-by":"publisher","first-page":"10110201102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. GLP-1 receptor agonists in the treatment of type 2 diabetes \u2014 state-of-the-art. Mol. Metab. 46, 10110201102 (2021).","journal-title":"Mol. Metab."},{"key":"1258_CR121","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa, S. Immortal time bias in pharmaco-epidemiology. Am. J. Epidemiol. 167, 492\u2013499 (2008).","journal-title":"Am. J. Epidemiol."},{"key":"1258_CR122","doi-asserted-by":"publisher","first-page":"154308","DOI":"10.1016\/j.metabol.2020.154308","volume":"110","author":"F Prattichizzo","year":"2020","unstructured":"Prattichizzo, F., de Candia, P., De Nigris, V., Nicolucci, A. & Ceriello, A. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: systematic review and meta-analyses of trials according to different scenarios. Metabolism 110, 154308 (2020).","journal-title":"Metabolism"},{"key":"1258_CR123","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/dom.15511","volume":"26","author":"SK Kunutsor","year":"2024","unstructured":"Kunutsor, S. K. et al. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes. Diabetes Obes. Metab. 26, 2069\u20132081 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"1258_CR124","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrendo.2017.3","volume":"13","author":"BP Kovatchev","year":"2017","unstructured":"Kovatchev, B. P. Metrics for glycaemic control \u2014 from HbA(1c) to continuous glucose monitoring. Nat. Rev. Endocrinol. 13, 425\u2013436 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1258_CR125","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S2213-8587(21)00245-X","volume":"10","author":"A Ceriello","year":"2022","unstructured":"Ceriello, A. et al. Glycaemic management in diabetes: old and new approaches. Lancet Diabetes Endocrinol. 10, 75\u201384 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1258_CR126","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12933-022-01445-4","volume":"21","author":"A Ceriello","year":"2022","unstructured":"Ceriello, A. et al. HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target. Cardiovascul. Diabetol. 21, 13 (2022).","journal-title":"Cardiovascul. Diabetol."},{"key":"1258_CR127","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-8587(18)30048-2","volume":"6","author":"A Forbes","year":"2018","unstructured":"Forbes, A., Murrells, T., Mulnier, H. & Sinclair, A. J. Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. Lancet Diabetes Endocrinol. 6, 476\u2013486 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1258_CR128","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/obr.12251","volume":"16","author":"JP Montani","year":"2015","unstructured":"Montani, J. P., Schutz, Y. & Dulloo, A. G. Dieting and weight cycling as risk factors for cardiometabolic diseases: who is really at risk? Obesity Rev. 16, 7\u201318 (2015).","journal-title":"Obesity Rev."},{"key":"1258_CR129","doi-asserted-by":"publisher","first-page":"e085304","DOI":"10.1136\/bmj-2025-085304","volume":"392","author":"S West","year":"2026","unstructured":"West, S. et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ 392, e085304 (2026).","journal-title":"BMJ"},{"key":"1258_CR130","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13679-023-00539-8","volume":"13","author":"N Sanaya","year":"2024","unstructured":"Sanaya, N., Janusaite, M., Dalamaga, M. & Magkos, F. The physiological effects of weight-cycling: a review of current evidence. Curr. Obes. Rep. 13, 35\u201350 (2024).","journal-title":"Curr. Obes. Rep."},{"key":"1258_CR131","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-08165-7","volume":"636","author":"LC Hinte","year":"2024","unstructured":"Hinte, L. C. et al. Adipose tissue retains an epigenetic memory of obesity after weight loss. Nature 636, 457\u2013465 (2024).","journal-title":"Nature"},{"key":"1258_CR132","doi-asserted-by":"publisher","first-page":"110646","DOI":"10.1016\/j.diabres.2023.110646","volume":"199","author":"F Prattichizzo","year":"2023","unstructured":"Prattichizzo, F., Frige, C., La Grotta, R. & Ceriello, A. Weight variability and diabetes complications. Diabetes Res. Clin. Pract. 199, 110646 (2023).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1258_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01360-0","volume":"20","author":"A Ceriello","year":"2021","unstructured":"Ceriello, A. et al. Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish national diabetes register. Cardiovasc. Diabetol. 20, 173 (2021).","journal-title":"Cardiovasc. Diabetol."},{"key":"1258_CR134","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s42255-022-00674-x","volume":"4","author":"O Bondareva","year":"2022","unstructured":"Bondareva, O. et al. Single-cell profiling of vascular endothelial cells reveals progressive organ-specific vulnerabilities during obesity. Nat. Metab. 4, 1591\u20131610 (2022).","journal-title":"Nat. Metab."},{"key":"1258_CR135","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cels.2017.12.013","volume":"6","author":"BD Piening","year":"2018","unstructured":"Piening, B. D. et al. Integrative personal omics profiles during periods of weight gain and loss. Cell Syst. 6, 157\u2013170.e8 (2018).","journal-title":"Cell Syst."},{"key":"1258_CR136","doi-asserted-by":"publisher","first-page":"912","DOI":"10.2337\/dc16-0157","volume":"39","author":"TD Adams","year":"2016","unstructured":"Adams, T. D., Arterburn, D. E., Nathan, D. M. & Eckel, R. H. Clinical outcomes of metabolic surgery: microvascular and macrovascular complications. Diabetes Care 39, 912\u2013923 (2016).","journal-title":"Diabetes Care"},{"key":"1258_CR137","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2213-8587(25)00295-5","volume":"14","author":"E Vazquez Arreola","year":"2026","unstructured":"Vazquez Arreola, E. et al. Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the diabetes prevention program outcome study and the daqing diabetes prevention outcome study. Lancet Diabetes Endocrinol. 14, 137\u2013148 (2026).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1258_CR138","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2337\/db24-1071","volume":"74","author":"S Leon","year":"2025","unstructured":"Leon, S. et al. GLP-1-mediated targeting of inflammation corrects obesogenic memory in male mice. Diabetes 74, 1525\u20131534 (2025).","journal-title":"Diabetes"},{"key":"1258_CR139","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/jan.15141","volume":"78","author":"S Atkinson-Briggs","year":"2022","unstructured":"Atkinson-Briggs, S., Jenkins, A., Ryan, C., Brazionis, L. & Centre for Research Excellence in Diabetic Retinopathy Study Group. Health-risk behaviours among Indigenous Australians with diabetes: a study in the integrated diabetes education and eye screening (iDEES) project. J. Adv. Nurs. 78, 1305\u20131316 (2022).","journal-title":"J. Adv. Nurs."},{"key":"1258_CR140","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/dme.14099","volume":"36","author":"D Xu","year":"2019","unstructured":"Xu, D. et al. Health-related behaviours in a remote Indigenous population with type 2 diabetes: a central Australian primary care survey in the telehealth eye and associated medical services network [TEAMSnet] project. Diabet. Med. 36, 1659\u2013167014099 (2019).","journal-title":"Diabet. Med."},{"key":"1258_CR141","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.1016\/j.jcjd.2015.09.090","volume":"39","author":"DC Lau","year":"2015","unstructured":"Lau, D. C. & Teoh, H. Impact of current and emerging glucose-lowering drugs on body weight in type 2 diabetes. Can. J. Diabetes 39, S148\u2013S154 (2015).","journal-title":"Can. J. Diabetes"},{"key":"1258_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102475","volume":"69","author":"SBK Jensen","year":"2024","unstructured":"Jensen, S. B. K. et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine 69, 102475 (2024).","journal-title":"EClinicalMedicine"},{"key":"1258_CR143","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.physbeh.2011.04.063","volume":"104","author":"SL Parylak","year":"2011","unstructured":"Parylak, S. L., Koob, G. F. & Zorrilla, E. P. The dark side of food addiction. Physiol. Behav. 104, 149\u2013156 (2011).","journal-title":"Physiol. Behav."},{"key":"1258_CR144","doi-asserted-by":"publisher","first-page":"101678","DOI":"10.1016\/j.bodyim.2023.101678","volume":"48","author":"JA Levinson","year":"2024","unstructured":"Levinson, J. A., Kinkel-Ram, S., Myers, B. & Hunger, J. M. A systematic review of weight stigma and disordered eating cognitions and behaviors. Body Image 48, 101678 (2024).","journal-title":"Body Image"},{"key":"1258_CR145","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/nu16081224","volume":"16","author":"B Zhou","year":"2024","unstructured":"Zhou, B., Roberts, S. B., Das, S. K. & Naumova, E. N. Weight loss trajectories and short-term prediction in an online weight management program. Nutrients 16, 1224 (2024).","journal-title":"Nutrients"},{"key":"1258_CR146","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.70017","volume":"10","author":"PT Katzmarzyk","year":"2024","unstructured":"Katzmarzyk, P. T. et al. Four-year follow-up of weight loss maintenance using electronic medical record data: the PROPEL trial. Obes. Sci. Pract. 10, e70017 (2024).","journal-title":"Obes. Sci. Pract."},{"key":"1258_CR147","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1123\/jpah.2012-0250","volume":"11","author":"VA Catenacci","year":"2014","unstructured":"Catenacci, V. A. et al. Dietary habits and weight maintenance success in high versus low exercisers in the National Weight Control Registry. J. Phys. Act. Health 11, 1540\u20131548 (2014).","journal-title":"J. Phys. Act. Health"},{"key":"1258_CR148","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/15598276241302273","volume":"19","author":"GA Sforzo","year":"2025","unstructured":"Sforzo, G. A., Gordon, N. F., Peeke, P. M. & Moore, M. Health and well-being coaching adjuvant to GLP-1 induced weight loss. Am. J. Lifestyle Med. 19, 652\u2013660 (2025).","journal-title":"Am. J. Lifestyle Med."},{"key":"1258_CR149","unstructured":"National Institute for Health and Care Excellence. Overweight and obesity management. NICE https:\/\/www.nice.org.uk\/guidance\/qs212\/chapter\/Quality-statement-7-Advice-and-support-after-stopping-medicines-for-weight-management-or-completing-behavioural-interventions (2025)."},{"key":"1258_CR150","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13731","volume":"75","author":"AB Jain","year":"2021","unstructured":"Jain, A. B. et al. Switching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance. Int. J. Clin. Pract. 75, e13731 (2021).","journal-title":"Int. J. Clin. Pract."},{"key":"1258_CR151","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","volume":"100","author":"CM Apovian","year":"2015","unstructured":"Apovian, C. M. et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 100, 342\u2013362 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1258_CR152","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","volume":"192","author":"S Wharton","year":"2020","unstructured":"Wharton, S. et al. Obesity in adults: a clinical practice guideline. CMAJ 192, E875\u2013E891 (2020).","journal-title":"CMAJ"},{"key":"1258_CR153","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1111\/dom.16313","volume":"27","author":"Z Siudak","year":"2025","unstructured":"Siudak, Z. et al. The extent and predictors of off-label use of GLP-1 receptor agonists for weight loss management. Diabetes Obes. Metab. 27, 3509\u20133511 (2025).","journal-title":"Diabetes Obes. Metab."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01258-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01258-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01258-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:02:07Z","timestamp":1786449727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01258-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":153,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1258"],"URL":"https:\/\/doi.org\/10.1038\/s41574-026-01258-5","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"28 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C. reports being on the advisory board, consultancy and giving lectures for Abbott, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Hikamr Pharma, Guidotti, Eli Lilly, MSD, Merck, Novo, Roche Diagnostics, Sanofi, Servier, and Sun Pharma. G.T.R. is on the advisory board and does consultancy and lectures for NovoNordisk, AstraZeneca, Sanofi, Boehringer, Lilly, Mundipharma and Sankyo. N.C. and A.J. are investigators on an investigator-initiated trial of tirzepatide in Indigenous Australians with T2DM and suboptimal glycaemia with drug provision by Eli Lilly (Australia). M.A.N. has been a member of advisory boards or has consulted with Boehringer Ingelheim, Eli Lilly & Co., Medtronic, Merck, Sharp & Dohme, NovoNordisk, Pfizer, Regor, Sun Pharma and Structure Therapeutics (ShouTi, Gasherbrum). He has received grant support from Merck, Sharp & Dohme. He has also served on the speakers\u2019 bureau of Eli Lilly & Co., Merck, Sharp & Dohme, Medscape, Medical Learning Institute, and NovoNordisk. He is on a data monitoring and safety board for Inventiva. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}